| X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization RL Camp, M Dolled-Filhart, DL Rimm Clinical cancer research 10 (21), 7252-7259, 2004 | 3464 | 2004 |
| The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ... Annals of oncology 26 (2), 259-271, 2015 | 2998 | 2015 |
| Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma LA Garraway, HR Widlund, MA Rubin, G Getz, AJ Berger, S Ramaswamy, ... Nature 436 (7047), 117-122, 2005 | 1827 | 2005 |
| Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features CJ Creighton, X Li, M Landis, JM Dixon, VM Neumeister, A Sjolund, ... Proceedings of the National Academy of Sciences 106 (33), 13820-13825, 2009 | 1660 | 2009 |
| Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrin KL Cepek, SK Shaw, CM Parker, GJ Russell, JS Morrow, DL Rimm, ... Nature 372 (6502), 190-193, 1994 | 1465 | 1994 |
| Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology K Bera, KA Schalper, DL Rimm, V Velcheti, A Madabhushi Nature reviews Clinical oncology 16 (11), 703-715, 2019 | 1307 | 2019 |
| Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update KH Allison, MEH Hammond, M Dowsett, SE McKernin, LA Carey, ... Journal of Clinical Oncology 38 (12), 1346-1366, 2020 | 1123 | 2020 |
| PD-L1 as a biomarker of response to immune-checkpoint inhibitors DB Doroshow, S Bhalla, MB Beasley, LM Sholl, KM Kerr, S Gnjatic, ... Nature reviews Clinical oncology 18 (6), 345-362, 2021 | 1093 | 2021 |
| Validation of tissue microarray technology in breast carcinoma RL Camp, LA Charette, DL Rimm Laboratory investigation 80 (12), 1943-1949, 2000 | 1062 | 2000 |
| Alpha 1 (E)-catenin is an actin-binding and-bundling protein mediating the attachment of F-actin to the membrane adhesion complex. DL Rimm, ER Koslov, P Kebriaei, CD Cianci, JS Morrow Proceedings of the National Academy of Sciences 92 (19), 8813-8817, 1995 | 1002 | 1995 |
| Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis PM Weinberger, Z Yu, BG Haffty, D Kowalski, M Harigopal, J Brandsma, ... Journal of clinical oncology 24 (5), 736-747, 2006 | 966 | 2006 |
| Programmed death ligand-1 expression in non-small cell lung cancer V Velcheti, KA Schalper, DE Carvajal, VK Anagnostou, KN Syrigos, ... Laboratory investigation 94 (1), 107-116, 2014 | 949 | 2014 |
| Automated subcellular localization and quantification of protein expression in tissue microarrays RL Camp, GG Chung, DL Rimm Nature medicine 8 (11), 1323-1328, 2002 | 910 | 2002 |
| Quantitative assessment of the heterogeneity of PD-L1 expression in non–small-cell lung cancer J McLaughlin, G Han, KA Schalper, D Carvajal-Hausdorf, V Pelekanou, ... JAMA oncology 2 (1), 46-54, 2016 | 887 | 2016 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (6), 311-335, 2017 | 795 | 2017 |
| Antibody validation J Bordeaux, AW Welsh, S Agarwal, E Killiam, MT Baquero, JA Hanna, ... Biotechniques 48 (3), 197-209, 2010 | 795 | 2010 |
| A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung cancer DL Rimm, G Han, JM Taube, SY Eunhee, JA Bridge, DB Flieder, R Homer, ... JAMA oncology 3 (8), 1051-1058, 2017 | 781 | 2017 |
| Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology … S Hendry, R Salgado, T Gevaert, PA Russell, T John, B Thapa, M Christie, ... Advances in anatomic pathology 24 (5), 235-251, 2017 | 697 | 2017 |
| Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer S Gettinger, J Choi, K Hastings, A Truini, I Datar, R Sowell, A Wurtz, ... Cancer discovery 7 (12), 1420-1435, 2017 | 688 | 2017 |
| Differences in risk factors for breast cancer molecular subtypes in a population-based study XR Yang, ME Sherman, DL Rimm, J Lissowska, LA Brinton, B Peplonska, ... Cancer Epidemiology Biomarkers & Prevention 16 (3), 439-443, 2007 | 638 | 2007 |
Roy S. Herbst, MD, PhDYale School of Medicine | Yale Cancer Center | Smilow Cancer Hospital at Yale-New HavenAdresse e-mail validée de yale.edu